Cerenome (PSTV) Liabilities from Discontinued Operations (2018 - 2019)
Plus Therapeutics (PSTV) posted quarterly Liabilities from Discontinued Operations of 2102000.0 for Q2 2019, up 757.96% quarter-over-quarter from 245000.0 in Q4 2018.
Cerenome (PSTV) Liabilities from Discontinued Operations (2018 - 2019) Analysis & Trends
Plus Therapeutics (PSTV) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 2102000.0 the latest figure, recorded in Q2 2019.
- In Q2 2019, Liabilities from Discontinued Operations changed N/A year-over-year to 2102000.0; the TTM figure through Jun 2019 stood at 2102000.0 (changed N/A YoY), while the FY2018 annual figure was 245000.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations grew to 2102000.0 in Q2 2019 per PSTV's latest filing, from 245000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 2102000.0 in Q2 2019 and bottomed at 245000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 2.10 Mn |
| Jun 30, 2019 | 2.10 Mn |
| Dec 31, 2018 | 245,000.00 |
| Dec 31, 2018 | 245,000.00 |